GOOD THERAPEUTICS

good-therapeutics-logo

Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.

#SimilarOrganizations #People #Financial #Website #More

GOOD THERAPEUTICS

Social Links:

Industry:
Biotechnology Life Science Pharmaceutical

Founded:
2016-01-01

Address:
Seattle, Washington, United States

Country:
United States

Website Url:
http://www.goodtherapeutics.com

Total Employee:
1+

Status:
Active

Contact:
(253) 271-4341

Email Addresses:
[email protected]

Total Funding:
30.2 M USD


Similar Organizations

antengene-corporation-logo

Antengene Corporation

Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.

arcellx-logo

Arcellx

Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.

axcella-logo

Axcella

Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.

geneos-therapeutics-logo

Geneos Therapeutics

Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.


Current Advisors List

john-mckearn_image

John McKearn Board Member @ Good Therapeutics
Board_member

monique-schiersing_image

Monique Schiersing Board Member @ Good Therapeutics
Board_member

nicholas-walrod_image

Nicholas Walrod Board Member @ Good Therapeutics
Board_member

Current Employees Featured

john-mulligan_image

John Mulligan
John Mulligan Founder and CEO @ Good Therapeutics
Founder and CEO

Founder


john-mulligan_image

John Mulligan

Investors List

rivervest_image

RiverVest

RiverVest investment in Series B - Good Therapeutics

roche-venture-fund_image

Roche Venture Fund

Roche Venture Fund investment in Series B - Good Therapeutics

3x5-partners_image

3ร—5 Partners

3ร—5 Partners investment in Series B - Good Therapeutics

digitalis-ventures_image

Digitalis Ventures

Digitalis Ventures investment in Series B - Good Therapeutics

roche-venture-fund_image

Roche Venture Fund

Roche Venture Fund investment in Series A - Good Therapeutics

codon-capital_image

Codon Capital

Codon Capital investment in Series A - Good Therapeutics

rivervest_image

RiverVest

RiverVest investment in Series A - Good Therapeutics

digitalis-ventures_image

Digitalis Ventures

Digitalis Ventures investment in Series A - Good Therapeutics

3x5-partners-658c_image

3x5 Partners

3x5 Partners investment in Series A - Good Therapeutics

rivervest_image

RiverVest

RiverVest investment in Series A - Good Therapeutics

Official Site Inspections

http://www.goodtherapeutics.com

  • Host name: 141.193.213.11
  • IP address: 141.193.213.11
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Good Therapeutics"

Good Therapeutics Company Profile 2024: Valuation, Investors ...

Good Therapeutics is headquartered in Seattle, WA. What is the size of Good Therapeutics? Good Therapeutics has 26 total employees. What industry is Good Therapeutics in? Good โ€ฆSee details»

Good Therapeutics, Inc. | LinkedIn

Good Therapeutics, Inc. | 3,746 followers on LinkedIn. Systemic delivery, local activity | At Good Therapeutics we are developing protein-based drugs with regulated, context-dependent activity.See details»

Roche acquires Good Therapeutics - 2022-09-07 - Crunchbase

Sep 7, 2022 Acquired Organization: Good Therapeutics Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is โ€ฆSee details»

Good Therapeutics - Funding, Financials, Valuation & Investors

Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. Search Crunchbase. ... How much funding has โ€ฆSee details»

Good Therapeutics Company Profile - Office Locations ... - Craft

Good Therapeutics is a biotechnology company developing protein drugs that sense biomarkers and respond with therapeutic activity. Its core technology is an algorithm for designing proteins โ€ฆSee details»

Good Therapeutics Announces Acquisition of โ€ฆ

Sep 7, 2022 Good Therapeutics Developing PD-1-regulated IL-2 Drugs Based on Innovative Conditionally Active Drug Technology September 07, 2022 07:00 AM Eastern Daylight TimeSee details»

Good Therapeutics lands $8M to develop protein drugs that

Dec 30, 2021 Good Therapeutics is developing an IL-2-based agent that is active when bound to immune T cells that recognize tumors. The therapeutic binds a target on such cells, PD-1, then โ€ฆSee details»

CASE STUDY: GOOD THERAPEUTICS - RiverVest

Aug 3, 2023 Good Therapeutics, founded in 2016 by molecular biologist John Mulligan, Ph.D., was acquired by Roche in 2022 for $250 million upfront plus potential milestone payments. Even better, Mulligan and company retained โ€ฆSee details»

Roche to acquire Good Therapeutics' lead drug โ€ฆ

Sep 7, 2022 Good Therapeutics previously raised $600,000 in Seed funding, $22 million in a Series A round in 2020 and $10 million in a recent Series B round. Roche Venture Fund is an investor.See details»

Seattle biotech startup Good Therapeutics raises $11M โ€ฆ

Feb 19, 2019 Good Therapeutics, a new Seattle biotech startup that aims to develop protein drugs that act only when needed, raised $11 million in an equity round, according to a new SEC filing.. The secretive ...See details»

Roche to Acquire Good Therapeutics for $250 Million - PharmTech

Sep 8, 2022 Good Therapeutics, a privately held biopharmaceutical company, announced on Sept. 7, 2022 that it has entered into a definitive merger to be acquired by Roche for $250 โ€ฆSee details»

Good Therapeutics Being Acquired by Roche for $250M

Sep 13, 2022 The whole Good Therapeutics team will be retained by Bonum. โ€œWith our proven track record in cancer immunotherapy, we are well-positioned to leverage our deep discovery, โ€ฆSee details»

Roche to pay $250M for Good Therapeutics and its targeted drug ...

Sep 7, 2022 Roche will pay $250 million in cash to take over privately held Good Therapeutics and gain access to a program designed to produce more selective cancer drugs. The deal, โ€ฆSee details»

Founder & CEO John Mulligan Shares Good Therapeutics

Jan 31, 2022 We founded Good Therapeutics to create a new kind of context-dependent drug that is active only when and where it is needed. When we started, many natural proteins were โ€ฆSee details»

Good Therapeutics raises $11M to develop โ€˜context ... - GeekWire

May 21, 2020 Seattle biotech startup Good Therapeutics raised another $11 million to create "context dependent" protein drugs that act only when needed. The 4-year-old. Toggle search โ€ฆSee details»

Roche pays $250 million to acquire Good Therapeutics - STAT

Sep 7, 2022 Good Therapeutics, a private company that raised just $30 million in venture financing since its 2016 foundation, said it had signed a deal to sell itself to Roche for $250 โ€ฆSee details»

Bonum Therapeutics Announces a $93M Series A Financing to โ€ฆ

Nov 15, 2022 Bonum is a spinout of Good Therapeutics, which Roche acquired in August 2022 for $250 million upfront plus potential milestone payments. The investor syndicate that โ€ฆSee details»

Good Therapeutics Strengthens Senior Management Team with

Dec 9, 2021 SEATTLE--(BUSINESS WIRE)--Good Therapeutics, Inc. today announced appointments of Diane Hollenbaugh, PhD and Neela Patel, PhD to the companyโ€™s senior โ€ฆSee details»

Bonum Therapeutics Raises $93M with Allosterically Regulated โ€ฆ

Nov 15, 2022 Bonum spun off from Good Therapeutics, which was acquired by Roche in August 2022 for a $250-million upfront payment with future milestone payments. The investor โ€ฆSee details»

linkstock.net © 2022. All rights reserved